TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02769403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMath EmWAVE Pro
Description: The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMath EmWAVE Pro
Description: The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure and Heart Rate
Description: All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Pressure and Heart Rate
Description: All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sick Days
Description: Sick days during the 12 week study period will be collected

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sick Days
Description: Sick days during the 12 week study period will be collected

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Satisfaction
Description: This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) \& Physician Assistants \[advance practice clinicians\], and nurses) and will be linked to the consented research participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Satisfaction
Description: This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) \& Physician Assistants \[advance practice clinicians\], and nurses) and will be linked to the consented research participant.
Study: NCT03256981

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT dose and fractionation dependent on site of metastasis and proximity to critical normal tissues.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TKI
Description: Continued background TKI alone
Study: NCT04355247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MethylPREDNISolone 80 Mg/mL Injectable Suspension
Description: * Patients will be admitted to a regular room in the hospital (not ICU)~* They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~* Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital.
Study: NCT04330352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based STOP touching your face practice
Description: 1. Remind yourself to STOP. Whatever you are doing in this moment (e.g. touching your month, pinching your nose, rubbing your eyes, resting your chin on your hands), pause for a minute. 2. Take a deep breath. This reconnects you with your body. Pay attention to your breathing and just allow yourself to continue to breathe normally and naturally. 3. Observe what is happening for you in this moment-including thoughts, feelings, and emotions (e.g. feel distracted, anxious or nervous?). What do you notice in your body (e.g. feel itchy or tingling on any part of your face)? You can be aware of anything: posture, sensations, tension in your body, or, once again, your breath. You might notice the sound around you. You might even notice your thoughts or emotions. 4. Proceed with whatever you were doing before you came to a STOP or something that you want to do in the moment (e.g. proceed with touching your face, or stop face-touching and take an alternative behavior).
Study: NCT01356160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9451 Placebo
Description: Placebo to match GS-9451 QD
Study: NCT01269866

Intervention type: DRUG
Group type: OTHER
Intervention: Cymbalta
Description: Cymbalta 60 to 120 mg PO QD
Study: NCT01261637

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 20ml saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Description: 0.25% ropivicaine (maximum 1.5mg/kg)
Study: NCT05249023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium butyrate bolus
Description: On the test day participants suffering from IBS and healthy participants will undergo a distal colonoscopy procedure for the collection of mucosal biopsy specimens pre- and post-administration of a sodium butyrate solution (100 mM) at a selected area in the descending colon. Biopsies will be obtained from the colon pre- and 90 min post-administration of the intervention solution. Blood samples will be collected before and at six time-points after the intervention solution administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium butyrate bolus
Description: On the test day participants suffering from IBS and healthy participants will undergo a distal colonoscopy procedure for the collection of mucosal biopsy specimens pre- and post-administration of a sodium butyrate solution (100 mM) at a selected area in the descending colon. Biopsies will be obtained from the colon pre- and 90 min post-administration of the intervention solution. Blood samples will be collected before and at six time-points after the intervention solution administration.
Study: NCT00960063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT02828878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic MPBC transplantation from matched related donor
Study: NCT00960063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study: NCT00355485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microdermabrasion
Description: Device: Bellamed microdermabrasion system produced by Bella products or the Altair Diamondtome System.~Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart.
Study: NCT00960063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT01391039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid microsphere
Description: Intravenous injection of 10 microL/kg once prior to ultrasound examination
Study: NCT04281446

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation
Description: Application of light at specific wavelength for interaction with biological tissue
Study: NCT00960063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study: NCT04274816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Intradermal injection of tremelimumab 7 days prior to sentinel node biopsy, with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
Study: NCT03865446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: anti-cancer agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: anti-cancer agent
Study: NCT00976131

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CoQ10
Description: Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CoQ10 Placebo
Description: Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoQ10 Placebo
Description: Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Standard of care chemotherapy medication used to treat cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Standard of care chemotherapy medication used to treat cancer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Standard of care chemotherapy medication used to treat cancer.
Study: NCT04281446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Application of light at specific wavelength for interaction with biological tissue
Study: NCT00311727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H5N1
Description: 232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
Study: NCT02523599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XaraColl
Description: Surgical implantation of 3 bupivacaine collagen implants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Plain collagen implant (vehicle)
Study: NCT01427751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone intravitreal implant
Description: Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
Study: NCT01864954

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web+phone
Description: We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web+phone
Description: We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
Study: NCT00531102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free flow oxygen
Description: Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
Study: NCT04208282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7 day infusion set
Description: 7 days survival of the sets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7 day infusion set
Description: 7 days survival of the sets
Study: NCT04328454

Intervention type: OTHER
Intervention: retrospective analysis
Description: The investigators retrospectively analyzed the hospitalized patients with COVID-19
Study: NCT04640077

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No intervention

Intervention type: DRUG
Group type: OTHER
Intervention: donanemab
Description: Administered IV
Study: NCT03689660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback Training
Description: biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional rehabilitation
Description: Participants will receive a 12-week conventional rehabilitation program.
Study: NCT00976131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard of care chemotherapy medication used to treat cancer.
Study: NCT03805802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active product
Description: Once daily consumption over the period of the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: active product
Description: Once daily consumption over the period of the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: reference product
Description: Once daily consumption over the period of the study
Study: NCT06402396

Intervention type: DRUG
Intervention: bDMARDS
Description: Patients at time of the PDQ assessment and up to 4 months thereafter being on ongoing bDMARDs treatment or on switch of bDMARD treatment.

Intervention type: DRUG
Intervention: bDMARDS
Description: Patients at time of the PDQ assessment and up to 4 months thereafter being on ongoing bDMARDs treatment or on switch of bDMARD treatment.
Study: NCT01497600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
Study: NCT02729220

Intervention type: OTHER
Group type: OTHER
Intervention: Bronchoscopy
Description: Sampling of airways

Intervention type: OTHER
Group type: OTHER
Intervention: Bronchoscopy
Description: Sampling of airways

Intervention type: OTHER
Group type: OTHER
Intervention: Bronchoscopy
Description: Sampling of airways

Intervention type: OTHER
Group type: OTHER
Intervention: Bronchoscopy
Description: Sampling of airways
Study: NCT05313113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. The training content included topics such as setting a comfortable environment and suitable position for the pregnant, when the fetus is active and asleep during the day, how to count and how to evaluate the movements. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
Study: NCT01497600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
Study: NCT01173016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laronidase
Description: Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
Study: NCT01068522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parenchymal Intracranial pressure monitor
Description: Treatment based on readings from Parenchymal intracranial pressure monitor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment based on clinical and imaging observations
Description: Treatment based on clinical and imaging observations.
Study: NCT01425801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977 0.313 μg
Description: Dry powder inhalation, once-daily, single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977 0.625 μg
Description: Dry powder inhalation, once-daily, single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977 1.25 μg
Description: Dry powder inhalation, once-daily, single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977 2.5 μg
Description: Dry powder inhalation, once-daily, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol 400 μg
Description: Pressurized inhalation suspension, once-daily, single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol placebo
Description: Pressurized inhalation, once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol placebo
Description: Pressurized inhalation, once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol placebo
Description: Pressurized inhalation, once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol placebo
Description: Pressurized inhalation, once-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol placebo
Description: Pressurized inhalation, once-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS100977 placebo
Description: Dry powder inhalation, once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS100977 placebo
Description: Dry powder inhalation, once-daily
Study: NCT02946281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Do CHANGE
Description: The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
Study: NCT01442480

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
Study: NCT04040374

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI-based diagnosis
Description: AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The expert endoscopists-based diagnosis
Description: The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
Study: NCT05329844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin 50 MG
Description: 50 mg Vildagliptin as single-dose per study period
Study: NCT01497600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
Study: NCT04048421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hvNOTES radical colectomy
Description: With the patient under general anesthesia, pneumoperitoneum is achieved. Three trocars are inserted, one 12 mm or 5 mm in the umbilicus and two 5 mm in the right and/or left flanks. Mobilization of the splenic flexure or the hepatic flexure is performed with an initial traditional laparoscopic approach. A single-port is inserted into the abdominal cavity transvaginally through the colpotomy. Then most of the procedures are performed transvaginally with conventional rigid laparoscopic instruments. The corresponding arteries and veins are divided. The mesocolon is mobilized. The small intestine/colon/rectum are then divided with stapler. The specimen is removed transvaginally. Intracorporeal anastomosis is performed as per the surgeon's standard of care. For sigmoidectomy, the colon is then exteriorized and the anvil is fixed in the colon. An end-to-end anastomosis is performed using a circular stapler. Drainage tubes may be used.
Study: NCT02545933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
Study: NCT05329844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG
Description: 50 mg Vildagliptin as single-dose per study period